Hypothesis

Aging-related decline in microbiota-derived indole-3-propionic acid (IPA) reduces pregnane X receptor (PXR) activity in intestinal epithelial cells, leading to impaired mitochondrial DNA (mtDNA) quality control and increased heteroplasmic mutations that compromise gut barrier integrity.

Mechanistic Rationale

1. IPA, produced by commensal Clostridia, is a potent PXR ligand that promotes expression of mitochondrial protective genes such as AKR1B7 and enhances Nrf2-mediated antioxidant responses (Microbiome-derived IPA and PXR; PXR-AKR1B7 mitochondrial protection).
2. PXR directly regulates mitochondrial nucleoid proteins (e.g., TFAM) and mitophagy regulators (e.g., PINK1, Parkin) through cross‑talk with PGC‑1α and Nrf2 pathways, thereby influencing mtDNA replication fidelity and removal of damaged genomes.
3. In aging, colonic IPA levels fall, diminishing PXR activation. This results in reduced TFAM binding, increased mtDNA replication errors, and accumulation of deleterious heteroplasmic variants, especially at loci known to expand after age 70 (mtDNA heteroplasmy accumulation).
4. Mutant mtDNA elevates reactive oxygen species and triggers inflammasome activation, weakening tight‑junction proteins and increasing intestinal permeability.

Predictions

• Older mice will show lower fecal IPA, decreased PXR target gene expression in colonic epithelium, and higher mtDNA heteroplasmy load compared with young counterparts.
• Oral IPA supplementation in aged mice will rescue PXR activity, restore TFAM‑mtDNA binding, lower heteroplasmy, and improve barrier function (measured by FITC‑dextran flux).
• Intestinal‑epithelial‑specific PXR knockout will mimic the aging phenotype even in young animals, accelerating mtDNA mutation accumulation and barrier loss.
• Pharmacologic activation of PXR with a non‑IPA agonist (e.g., pregnenolone‑16α‑carbonitrile) will compensate for IPA loss and protect mtDNA integrity.

Experimental Approach

1. Cohort analysis – Collect feces and colonic mucosa from 3‑month and 24‑month mice; quantify IPA by LC‑MS, measure PXR target mRNA (AKR1B7, CYP3A11), assess mtDNA heteroplasmy via duplex sequencing, and evaluate permeability.
2. Intervention – Treat aged mice with IPA (10 mg/kg/day) or vehicle for 8 weeks; repeat measurements.
3. Genetic models – Use Villin‑Cre;Pxr^fl/fl mice to delete PXR specifically in gut epithelium; compare mtDNA heteroplasmy and barrier metrics with wild‑type litterns.
4. Rescue – Administer a synthetic PXR agonist to knockout mice to test whether downstream effects are ligand‑independent.
5. Readouts – Western blot for TFAM, PINK1, Parkin; immunofluorescence for tight‑junction proteins (occludin, ZO‑1); ROS assays (MitoSOX); inflammasome activation (caspase‑1 cleavage).

Potential Outcomes

• If IPA‑PXR signaling sustains mtDNA quality, supplementation will reduce heteroplasmy and restore barrier function, supporting the hypothesis.
• If PXR loss reproduces aging‑like mtDNA damage despite normal IPA levels, it confirms PXR as a downstream mediator.
• Failure of IPA to affect heteroplasmy would refute the proposed axis and suggest alternative mechanisms for mtDNA aging.

This framework directly tests whether a microbiome‑metabolite‑PXR pathway guards the mitochondrial genome in the gut, linking the "wrong genome" idea to a tractable, targetable mechanism.